PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Key Therapeutic Areas to Remain Strongest Drivers of CRO Revenue Growth in the United States Finds Frost & Sullivan - Strong investments from Pharmaceutical and Biotechnology companies
Key Therapeutic Areas to Remain Strongest Drivers of CRO Revenue Growth in the United States Finds Frost & Sullivan


NewswireToday - /newswire/ - Mountain View, CA, United States, 2009/09/21 - Strong investments from Pharmaceutical and Biotechnology companies.

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


The economic downturn and reduction in funding for early stage projects is likely to result in a decline in growth rate across major therapeutic segments in the short-to-medium term. However, due to this lack of funding, it is unlikely that pharmaceutical and biotechnology companies will invest in in-house capabilities to conduct clinical trials. This is set to benefit contract research organizations (CROs) in obtaining continued business from this segment. Despite possible defaults on payments for projects from a few companies that could affect CROs in the short-term, oncology, central nervous system, and cardiovascular are expected to remain as key therapeutic areas.

New analysis from Frost & Sullivan (, U.S. CRO Markets - Key Therapeutic Areas, finds that the market earned revenues of over $10.91 billion in 2009 and estimates this to reach $22.87 billion in 2015. The markets covered in this research include preclinical to phase IV CRO services for pharmaceuticals and biotechnology.

If you are interested in a virtual brochure, which provides a brief synopsis of the research and a table of contents, then send an email to Johanna Haynes at johanna.haynes[.], with your full name, company name, title, telephone number, company email address, company website, city, state and country.

"The most interesting aspect of CRO market growth has been that of new sponsors – increasingly biotechnology companies and specialty pharmaceutical companies – with a demand for full services spanning the pre-clinical to the post-commercialization stage," says Frost & Sullivan Senior Industry Analyst Barath Shankar Subramanian. "This could be attributed to the limited development infrastructure with sponsors, leading to CROs being viewed as strategic partners.."

Earlier, the trend in the market used to be start-up pharmaceutical and biotechnology companies out-licensing their product beyond phase I/II or getting acquired, which posed a great deal of uncertainty over the future of the project. Nowadays, companies are increasingly retaining products within their pipeline and continuing to take them closer to the market through CROs, thereby enhancing the value of the products and the company.

Despite optimistic forecasts for the market, a growing divide between patient access and studies is threatening productivity. Trials continue to become increasingly complex and global, resulting in intense competition for access to patients, new investigators, and innovative studies.

The divide between patient access and studies has been rising consistently over the past decade and could affect future studies. For studies that depend heavily on the emerging markets, this could have a negative impact on productivity by lengthening trial times. In addition, an underlying churn in existing investigators is further widening this divide.

"CROs and sponsors are looking at innovative ways to increase access to patients by partnering with patient recruitment firms," concludes Subramanian. "Service providers are also outsourcing large-scale global trials through the expanded reach of CRO partners, enabling access to an extensive patient pool."

U.S. CRO Markets - Key Therapeutic Areas is part of the Pharmaceuticals & Biotechnology Growth Partnership Services program, which also includes research in the following markets: U.S. Contract Research Organizations Markets; Global CRO Spending Trends; Global Biopharmaceutical Contract Manufacturing Market; and Strategic Analysis of Opportunities in the CRO Market – Phase 0. All research services included in subscriptions provide detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, enables clients to accelerate growth and achieve best in class positions in growth, innovation and leadership. The company's Growth Partnership Service provides the CEO and the CEO's Growth Team with disciplined research and best practice models to drive the generation, evaluation, and implementation of powerful growth strategies. Frost & Sullivan leverages over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 35 offices on six continents.

U.S. CRO Markets - Key Therapeutic Areas / N579

Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


Written by / Agency / Source: Frost & Sullivan


Availability: All Regions (Including Int'l)


Traffic Booster: [/] Quick Newswire Today Visibility Checker


Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

# # #

  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!

Key Therapeutic Areas to Remain Strongest Drivers of CRO Revenue Growth in the United States Finds Frost & Sullivan

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Johanna Haynes 
210.247.3870 johanna.haynes[.]
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Read Latest Articles From Frost & Sullivan / Company Profile

Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe
FDA Grants Priority Review to Genentech’s Lucentis® (Ranibizumab Injection) Supplemental Biologics License Application
Genentech’s TECENTRIQ® (Atezolizumab) Shows Significant Survival Advantage Compared to Chemotherapy
Greenphire Continues Commitment to Clinical Research Site Sustainability and Innovation at Global Site Solutions Summit
Frost & Sullivan Highlights argenx for Enhancing the Therapeutic Qualities of Human Antibodies with its Proprietary Antibody Discovery Platform, SIMPL
FDA Grants Breakthrough Therapy Designation for Genentech’s Actemra® (Tocilizumab) in Giant Cell Arteritis, a Form of Vasculitis
MDxHealth Announces Agreement with SouthGenetics for Distribution of SelectMDx in Central/South America
BD and Apax Partners Announce Closing of Joint Venture to Launch Global Respiratory Business
Exosome Diagnostics Enters Agreement with Amgen
Sartorius Stedim Biotech Launches Two Single-use Sartocon® Loop Assemblies with Integrated Polyethersulfone (PESU) Membrane
BD Expands Efforts to Combat Antimicrobial Resistance with New Automated ID/AST System

Boost Your Social Network
& Crowdfunding Campaigns

NewswireToday Celebrates 10 Years in Business


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  NAKIVO, Inc.

  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (